Panacea Biotec sells its domestic formulations business to Mankind Pharma
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
The vaccines are currently only authorised for emergency use in the country
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Subscribe To Our Newsletter & Stay Updated